Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016049 | Colorectum | AD | cell growth | 143/3918 | 482/18723 | 2.83e-06 | 8.09e-05 | 143 |
GO:0001558 | Colorectum | AD | regulation of cell growth | 124/3918 | 414/18723 | 7.67e-06 | 1.86e-04 | 124 |
GO:00015581 | Colorectum | SER | regulation of cell growth | 90/2897 | 414/18723 | 4.00e-04 | 6.02e-03 | 90 |
GO:00160491 | Colorectum | SER | cell growth | 100/2897 | 482/18723 | 1.07e-03 | 1.24e-02 | 100 |
GO:00160492 | Colorectum | MSS | cell growth | 123/3467 | 482/18723 | 7.15e-05 | 1.21e-03 | 123 |
GO:00015582 | Colorectum | MSS | regulation of cell growth | 105/3467 | 414/18723 | 2.97e-04 | 3.90e-03 | 105 |
GO:00160493 | Colorectum | FAP | cell growth | 112/2622 | 482/18723 | 2.40e-08 | 2.30e-06 | 112 |
GO:00015583 | Colorectum | FAP | regulation of cell growth | 95/2622 | 414/18723 | 5.02e-07 | 2.61e-05 | 95 |
GO:00160494 | Colorectum | CRC | cell growth | 95/2078 | 482/18723 | 1.51e-08 | 2.75e-06 | 95 |
GO:00015584 | Colorectum | CRC | regulation of cell growth | 78/2078 | 414/18723 | 1.84e-06 | 9.11e-05 | 78 |
GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
GO:000155821 | Liver | HCC | regulation of cell growth | 228/7958 | 414/18723 | 1.34e-07 | 2.55e-06 | 228 |
GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
GO:001604918 | Oral cavity | LP | cell growth | 155/4623 | 482/18723 | 1.08e-04 | 1.31e-03 | 155 |
GO:000155817 | Oral cavity | LP | regulation of cell growth | 134/4623 | 414/18723 | 2.25e-04 | 2.41e-03 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MUC12 | SNV | Missense_Mutation | | c.12902N>T | p.Thr4301Ile | p.T4301I | Q9UKN1 | protein_coding | deleterious(0) | possibly_damaging(0.711) | TCGA-B5-A0JN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | SD |
MUC12 | SNV | Missense_Mutation | rs144292724 | c.14036N>A | p.Arg4679His | p.R4679H | Q9UKN1 | protein_coding | tolerated(0.36) | possibly_damaging(0.711) | TCGA-B5-A0JV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MUC12 | SNV | Missense_Mutation | novel | c.8620N>G | p.Thr2874Ala | p.T2874A | Q9UKN1 | protein_coding | deleterious(0.02) | unknown(0) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
MUC12 | SNV | Missense_Mutation | | c.10739N>T | p.Ser3580Ile | p.S3580I | Q9UKN1 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
MUC12 | SNV | Missense_Mutation | | c.12815N>T | p.Ser4272Phe | p.S4272F | Q9UKN1 | protein_coding | tolerated(0.05) | possibly_damaging(0.692) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
MUC12 | SNV | Missense_Mutation | novel | c.13000N>C | p.Asn4334His | p.N4334H | Q9UKN1 | protein_coding | tolerated_low_confidence(0.13) | benign(0.034) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
MUC12 | SNV | Missense_Mutation | novel | c.7385N>G | p.Gln2462Arg | p.Q2462R | Q9UKN1 | protein_coding | tolerated(0.2) | unknown(0) | TCGA-B5-A0K8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
MUC12 | SNV | Missense_Mutation | | c.1189A>G | p.Lys397Glu | p.K397E | Q9UKN1 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MUC12 | SNV | Missense_Mutation | | c.4811C>A | p.Ser1604Tyr | p.S1604Y | Q9UKN1 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MUC12 | SNV | Missense_Mutation | novel | c.9482C>A | p.Ser3161Tyr | p.S3161Y | Q9UKN1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |